expansion

The Swedish bioinformatics firm sees its greatest growth potential in precision cancer diagnostics as it prepares to go public in the next 12 months.

The firm's technology uses ex vivo organ culture to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs.